GSK’s Drug Combo Shown to Cut Risk Of Death by 42% in Type Of Blood Cancer

Medscape December 9, 2024

(Reuters) – British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.

An interim analysis of data from a trial dubbed ‘DREAMM-7’ showed the drug in combination with the drug bortezomib plus the steroid dexamethasone showed statistically significant overall survival results compared to a standard of care daratumumab combination as a second line or later treatment of relapsed or refractory multiple myeloma, GSK said.

Multiple myeloma is the third most common type of blood cancer and is generally considered treatable but not curable.

The data projects that on...

Today's Sponsors

Today's Sponsor